Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
STRM.BIO has developed a proprietary, large capacity EV-based therapy for in vivo nucleic acid and protein delivery that specifically targets hematopoietic stem cells (HSCs) in bone marrow, is amenable to large scale commercial manufacture and presents with low immunogenicity.
Lead Product(s): EV-based Gene Therapy
Therapeutic Area: Rare Diseases and Disorders Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: National Center for Advancing Translational Sciences
Deal Size: $2.1 million Upfront Cash: Undisclosed
Deal Type: Funding July 26, 2022